Morris RE et al. |
Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. |
1990 |
Transplant. Proc. |
pmid:1689885
|
Li PK et al. |
The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. |
1990 |
Adverse Drug React Acute Poisoning Rev |
pmid:1703724
|
Todo S et al. |
Early trials with FK 506 as primary treatment in liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689886
|
McCauley J et al. |
The effects of FK 506 on renal function after liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689887
|
Kang Y et al. |
Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689889
|
Jain AB et al. |
FK 506 dosage in human organ transplantation. |
1990 |
Transplant. Proc. |
pmid:1689890
|
Demetris AJ et al. |
Pathologic observations in human allograft recipients treated with FK 506. |
1990 |
Transplant. Proc. |
pmid:1689891
|
Shapiro R et al. |
The side effects of FK 506 in humans. |
1990 |
Transplant. Proc. |
pmid:1689892
|
Van Thiel DH et al. |
Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. |
1990 |
Transplant. Proc. |
pmid:1689893
|
Hoffman AL et al. |
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. |
1990 |
Transplantation |
pmid:1690469
|
Woo J et al. |
The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. |
1990 |
Scand. J. Immunol. |
pmid:1690915
|
Yasunami Y et al. |
FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. |
1990 |
Transplantation |
pmid:1691535
|
Metcalfe SM and Richards FM |
Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. |
1990 |
Transplantation |
pmid:1691537
|
Morimoto T et al. |
Pancreaticoduodenal allotransplantation with FK 506 in the dog. |
1990 |
Transplant. Proc. |
pmid:1691550
|
Yasunami Y et al. |
Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. |
1990 |
Transplant. Proc. |
pmid:1691557
|
Thomson AW |
FK-506 enters the clinic. |
1990 |
Immunol. Today |
pmid:1692221
|
Saitoh Y et al. |
Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. |
1990 |
Jpn J Surg |
pmid:1692892
|
Rosen MK et al. |
Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. |
1990 |
Science |
pmid:1693013
|
Murase N et al. |
Prevention of spontaneous diabetes in BB rats with FK 506. |
1990 |
Lancet |
pmid:1697397
|
Justice RM et al. |
The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. |
1990 |
Biochem. Biophys. Res. Commun. |
pmid:1697463
|
Todo S et al. |
Liver, kidney, and thoracic organ transplantation under FK 506. |
1990 |
Ann. Surg. |
pmid:1697743
|
Sakr MF et al. |
FK 506 ameliorates the hepatic injury associated with ischemia. |
1990 |
Life Sci. |
pmid:1698241
|
Kurasawa K et al. |
The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. |
1990 |
Clin. Immunol. Immunopathol. |
pmid:1698584
|
Miyagawa J et al. |
Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. |
1990 |
Diabetologia |
pmid:1698679
|
Lagodzinski Z et al. |
Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. |
1990 |
Immunology |
pmid:1698713
|
Kawashima H et al. |
Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. |
1990 |
Invest. Ophthalmol. Vis. Sci. |
pmid:1702408
|
Wilkinson PC and Watson EA |
FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. |
1990 |
Immunology |
pmid:1702750
|
Metcalfe S and Milner J |
Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. |
1990 |
Immunol. Lett. |
pmid:1702753
|
Takada K et al. |
Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. |
1990 |
J. Chromatogr. |
pmid:1703552
|
Woo J et al. |
Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. |
1990 |
Immunology |
pmid:1703987
|
Wasik M et al. |
Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. |
1990 Jul-Aug |
Immunopharmacology |
pmid:1699911
|
MacLeod AM and Thomson AW |
[FK-506. A new immunosuppressive drug]. |
1990 Jul-Sep |
Medicina (Firenze) |
pmid:1706817
|
Naouri A and Tissot E |
[Indications for liver transplantation in adults]. |
1990 Jun-Jul |
J Chir (Paris) |
pmid:1698800
|
Gailliot FP et al. |
Fluidized bed adsorption for whole broth extraction. |
1990 Sep-Oct |
Biotechnol. Prog. |
pmid:1366874
|
Goto T et al. |
FK 506: historical perspectives. |
1991 |
Transplant. Proc. |
pmid:1721254
|
Ochiai T et al. |
Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. |
1991 |
Transplant. Proc. |
pmid:1721255
|
Siekierka JJ et al. |
Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721256
|
Morris RE |
In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. |
1991 |
Transplant. Proc. |
pmid:1721257
|
Kobayashi M et al. |
FK 506 assay past and present--characteristics of FK 506 ELISA. |
1991 |
Transplant. Proc. |
pmid:1721258
|
Warty VS et al. |
Practical aspects of FK 506 analysis (Pittsburgh experience). |
1991 |
Transplant. Proc. |
pmid:1721259
|
Müller MK et al. |
Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. |
1991 |
Transplant. Proc. |
pmid:1721286
|
Francavilla A et al. |
The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. |
1991 |
Transplant. Proc. |
pmid:1721287
|
Blanc P et al. |
Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. |
1991 |
Transplant. Proc. |
pmid:1721288
|
Loréal O et al. |
FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. |
1991 |
Transplant. Proc. |
pmid:1721289
|
McCauley J et al. |
Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. |
1991 |
Transplant. Proc. |
pmid:1721290
|
McLachlan G et al. |
Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. |
1991 |
Transplant. Proc. |
pmid:1721291
|
Yagihashi A et al. |
The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721318
|
Woo J et al. |
Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. |
1991 |
Transplant. Proc. |
pmid:1721319
|
Chen-Woan M et al. |
Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721320
|
Fukuzawa M et al. |
Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. |
1991 |
Transplant. Proc. |
pmid:1721321
|
Takaori K et al. |
Effects of FK 506 on in vivo immunity in comparison to cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721322
|
Felser I et al. |
Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721350
|
Alessiani M et al. |
CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721351
|
Green M et al. |
Infectious complications of pediatric liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721352
|
Torre-Cisneros J et al. |
The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721353
|
Paul AA et al. |
CMV retinitis and the use of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721354
|
Reyes J et al. |
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721355
|
Frayha HH et al. |
Lymphoproliferative disorder in a liver transplant patient on FK 506. |
1991 |
Lancet |
pmid:1703258
|
Burman K and Crawford DH |
Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. |
1991 |
Lancet |
pmid:1703259
|
Nalesnik MA et al. |
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. |
1991 |
Transplant. Proc. |
pmid:1703335
|
Armitage JM et al. |
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. |
1991 |
Transplant. Proc. |
pmid:1703336
|
Gordon RD et al. |
Liver transplantation under cyclosporine: a decade of experience. |
1991 |
Transplant. Proc. |
pmid:1703339
|
Moutabarrik A et al. |
FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. |
1991 |
Transplant. Proc. |
pmid:1721382
|
Moutabarrik A et al. |
In vitro FK 506 kidney tubular cell toxicity. |
1991 |
Transplant. Proc. |
pmid:1721383
|
McCauley J et al. |
Changes in renal function after liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721385
|
Tauxe WN et al. |
A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721386
|
McCauley J et al. |
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721387
|
Ohtsuka S et al. |
The effect of short-term FK 506 therapy on pancreas transplantation in rats. |
1991 |
Transplant. Proc. |
pmid:1721413
|
Yamashita T et al. |
Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721414
|
Fukuzaki T et al. |
Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. |
1991 |
Transplant. Proc. |
pmid:1721415
|
Tzakis AG et al. |
FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721416
|
Masaoka T et al. |
Phase II study of FK 506 for allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721417
|
Markus PM et al. |
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721418
|
Ziccardi VB et al. |
Maxillofacial considerations in orthotopic liver transplantation. |
1991 |
Oral Surg. Oral Med. Oral Pathol. |
pmid:1704494
|
Bierer BE et al. |
The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. |
1991 |
Eur. J. Immunol. |
pmid:1705513
|
Heitman J et al. |
FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1705713
|
Goebl MG |
The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. |
1991 |
Cell |
pmid:1706222
|
de Paulis A et al. |
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. |
1991 |
J. Immunol. |
pmid:1706398
|
Lin CY et al. |
Effects of FK 506 on the biochemical markers in canine lung allograft rejection. |
1991 |
Transplant. Proc. |
pmid:1721445
|
Propper DJ et al. |
Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. |
1991 |
Transplant. Proc. |
pmid:1721446
|
Fabrega AJ et al. |
FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. |
1991 |
Transplant. Proc. |
pmid:1721447
|
Davies CB et al. |
Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. |
1991 |
Transplant. Proc. |
pmid:1721448
|
Abu-Elmagd K et al. |
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. |
1991 |
Transplant. Proc. |
pmid:1721449
|
Nikolaidis NL et al. |
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. |
1991 |
Transplant. Proc. |
pmid:1721450
|
Sigal NH et al. |
Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. |
1991 |
Transplant. Proc. |
pmid:1712132
|
Fung JJ et al. |
Current status of FK 506 in liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1712133
|
Francavilla A et al. |
Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. |
1991 |
Hepatology |
pmid:1712337
|
Aoki H |
[FK 506, a new immunosuppressant produced by a Streptomyces]. |
1991 |
Nippon Rinsho |
pmid:1712403
|
Hultsch T et al. |
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1712484
|
Nielsen JB et al. |
Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. |
1991 |
Biochemistry |
pmid:2043618
|
Ochiai T et al. |
[Immunosuppressive agents--advances of the developmental studies and the mode of action]. |
1991 |
Nippon Rinsho |
pmid:1715926
|
Jiang H et al. |
Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. |
1991 |
Eur Surg Res |
pmid:1723683
|
Liu J et al. |
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. |
1991 |
Cell |
pmid:1715244
|
Sakai K et al. |
[The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. |
1991 |
No To Shinkei |
pmid:1716937
|
Henderson DJ et al. |
Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. |
1991 |
Immunology |
pmid:1715317
|
DeFranco AL |
Signal transduction. Immunosuppressants at work. |
1991 |
Nature |
pmid:1715515
|
Flanagan WM et al. |
Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. |
1991 |
Nature |
pmid:1715516
|
Fujino Y et al. |
FK506 treatment of S-antigen induced uveitis in primates. |
1991 |
Curr. Eye Res. |
pmid:1717199
|
McWhinnie DL and Morris PJ |
Combination drug therapies for immunosuppression in transplantation. |
1991 |
Ann. Acad. Med. Singap. |
pmid:1724724
|
Pourtier-Manzanedo A et al. |
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. |
1991 |
Anticancer Drugs |
pmid:1724925
|